Insulin Pumps Market Size & Growth Forecast 2027–2036, By Segments (End-use, Product, Type, Accessories), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Insulin Pumps Market size stood at USD 7.8 billion in 2026 and is predicted to grow at a 7.41% CAGR from 2027 to 2036, exceeding USD 15.94 billion by 2036. The industry revenue for 2027 is calculated at USD 8.29 billion.

• Base Year Value (2026): USD 7.8 billion
• CAGR (2027-2036): 7.41%
• Forecast Year Value (2036): USD 15.94 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Insulin Pumps Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds 48.26% share, driven by advanced diabetes care adoption, strong reimbursement systems, CGM integration, and clinician familiarity with intensive insulin delivery technologies.
  • Asia Pacific is growing at 9.38% CAGR due to rising diabetes prevalence, improving diagnosis rates, expanding urban healthcare access, and increasing adoption of modern insulin delivery devices.

• Segment Momentum:

  • Hospitals accounted for 47.06% of the market in 2026 due to their central role in pump initiation, dose adjustment, specialist supervision, and management of complex insulin-dependent cases.
  • Disposable Pumps are the fastest-growing product segment because they offer a more convenient and less burdensome insulin delivery format, appealing to users seeking simpler day-to-day diabetes management.

• Market Expansion Drivers:

  • Rising diabetes and obesity prevalence accelerating adoption of advanced insulin delivery technologies.
  • Integration of continuous glucose monitoring and automated insulin delivery improving diabetes management outcomes.
  • Growing demand for connected and tubeless insulin pumps enhancing patient convenience and remote monitoring capabilities.

• Leading Market Participants:

  Leading players in the insulin pumps market include Medtronic plc (Ireland), Insulet Corporation (United States), Tandem Diabetes Care, Inc. (United States), Roche Holding AG (Switzerland), Ypsomed AG (Switzerland), Sanofi S.A. (France), SOOIL Development Co., Ltd. (South Korea), Cellnovo Group S.A. (France), Valeritas Holdings, Inc. (United States), Jiangsu Delfu Medical Device Co., Ltd. (China).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 7.8 billion
  • 2027 Estimated Market Size: USD 8.29 billion.
  • Projected Market Size: USD 15.94 billion by 2036
  • Growth Forecasts: 7.41% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hospitals (End-use) | Tethered Pumps (Product) | Traditional Insulin Pumps (Type) | Infusion Sets (Accessories)
  • Emerging Opportunity Segment: Homecare Settings (End-use) | Disposable Pumps (Product) | Patch Pumps (Type) | Reservoirs (Accessories)

Market Growth Drivers and Industry Trends

Rising diabetes and obesity prevalence accelerating adoption of advanced insulin delivery technologies

Increasing prevalence of diabetes and obesity is expanding the number of patients requiring effective long-term glucose and insulin management, which will drive the insulin pumps market growth. Insulin pumps provide continuous delivery of insulin and can offer greater flexibility in managing changing insulin requirements compared with multiple manual injections. As patients and healthcare providers seek treatment approaches that support more consistent insulin administration and individualized diabetes management, advanced pump-based delivery systems are gaining greater relevance.

Integration of continuous glucose monitoring and automated insulin delivery improving diabetes management outcomes

Combining insulin pumps with continuous glucose monitoring is enabling more responsive diabetes management by linking glucose information with insulin delivery decisions, thereby propelling insulin pumps market growth. Integrated systems can continuously track glucose levels and, where automated functionality is available, adjust insulin delivery according to detected changes. This connectivity reduces reliance on isolated monitoring and manual intervention while providing patients and clinicians with more comprehensive information for managing glucose levels and treatment patterns.

Growing demand for connected and tubeless insulin pumps enhancing patient convenience and remote monitoring capabilities

Patient preference for less restrictive and more digitally connected treatment options is increasing interest in tubeless and connected pump technologies, supporting insulin pumps market growth. Tubeless designs can reduce the inconvenience associated with conventional tubing and provide greater flexibility during daily activities, while connected systems can transmit treatment and device information for remote monitoring. These capabilities can facilitate ongoing communication between patients and healthcare providers while giving users greater freedom in managing insulin delivery during everyday routines.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising diabetes and obesity prevalence accelerating adoption of advanced insulin delivery technologies	2.20%	Moderate	North America, Asia Pacific	High	Near Term
Integration of continuous glucose monitoring and automated insulin delivery improving diabetes management outcomes	2.00%	High	North America, Europe	High	Mid Term
Growing demand for connected and tubeless insulin pumps enhancing patient convenience and remote monitoring capabilities	1.70%	Moderate	Asia Pacific, North America	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

The North America insulin pumps market held the largest share of 48.26% in 2026, supported by advanced diabetes care infrastructure, strong adoption of automated and connected medical devices, and increasing preference for technologies that enable continuous and personalized insulin delivery. Insulin pumps can provide greater flexibility in diabetes management compared with conventional administration approaches, supporting demand among patients and healthcare providers seeking more integrated treatment options. The region's established medical technology ecosystem and emphasis on digital health are also facilitating the integration of pumps with monitoring and data-management technologies. Continued innovation in device functionality and growing interest in personalized disease management are reinforcing regional demand.

Asia Pacific represents the fastest-growing region in the insulin pumps market, benefiting from expanding healthcare infrastructure, increasing diabetes awareness, and improving access to advanced treatment technologies. Greater recognition of the benefits of intensive and personalized diabetes management is encouraging interest in insulin pump therapy, while improvements in specialist healthcare services are supporting wider adoption. The expansion of healthcare facilities and increasing availability of medical technologies are helping reduce barriers to advanced diabetes treatment. Moreover, growing interest in connected healthcare and digitally enabled disease management is creating additional opportunities for insulin pumps, supporting the region's rapid market development.

Key Country Insights

United States

Digital Diabetes Management

The U.S. insulin pumps market increasingly integrates connected technologies with continuous glucose monitoring to improve diabetes management. U.S. healthcare providers prioritize user-friendly systems that support personalized insulin delivery and better long-term treatment adherence.

Japan

Compact Device Preference

Japan values compact, reliable insulin pumps that fit everyday lifestyles while maintaining precise insulin delivery. Japanese manufacturers continue refining wearable technologies that improve comfort, usability, and long-term patient acceptance.

South Korea

Connected Care Ecosystem

South Korea advances insulin pump adoption through digitally connected diabetes management solutions and expanding healthcare technology infrastructure. South Korean providers increasingly emphasize integrated monitoring capabilities that strengthen patient engagement and treatment efficiency.

Germany

Clinical Technology Adoption

Germany focuses on insulin pump technologies that improve dosing precision and support evidence-based diabetes care. German healthcare providers increasingly adopt advanced pump systems with enhanced safety features and interoperability across diabetes management platforms.

France

Personalized Diabetes Care

France promotes insulin pump use as part of individualized diabetes management strategies that support better treatment outcomes. French healthcare providers increasingly encourage advanced pump technologies that improve patient convenience and consistent insulin administration.

Italy

Outpatient Therapy Support

Italy emphasizes insulin pumps that enable effective diabetes management beyond hospital settings through reliable wearable technologies. Italian healthcare providers increasingly encourage practical pump solutions that simplify long-term therapy while supporting patient independence.

Segment Leadership and Growth Trends

 

End-use Segment Analysis: Hospitals (Largest Segment) vs Homecare Settings (Fastest-Growing Segment)

In the insulin pumps market, hospitals accounted for the largest share of 47.06% in 2026, supported by their importance in initiating insulin pump therapy, evaluating patients, and providing clinical supervision. Hospital-based care offers access to endocrinology expertise, diabetes management resources, and the monitoring capabilities required to establish appropriate pump use. Healthcare professionals can also provide education and device guidance, helping patients transition effectively to insulin pump-based treatment.

Homecare settings are advancing at the fastest pace as diabetes management increasingly emphasizes convenience, patient independence, and continuous therapy outside traditional healthcare facilities. Insulin pumps enable patients to manage insulin delivery within their daily routines while reducing the need for frequent facility-based administration. Growing preference for personalized and flexible diabetes care is therefore supporting the wider adoption of pump-based therapy in home environments.

Product Segment Analysis: Tethered Pumps (Largest Segment) vs Disposable Pumps (Fastest-Growing Segment)

Tethered pumps represented the largest share of the insulin pumps market in 2026, reflecting their established role in providing continuous and controlled insulin delivery. These systems connect the pump to the patient through an infusion set, enabling consistent administration while allowing users to adjust delivery according to their treatment requirements. Their established clinical use, familiarity among healthcare professionals, and ability to support intensive insulin management continue to sustain demand for tethered pump systems.

Disposable pumps are expected to grow at the fastest rate as patients and healthcare providers seek simpler insulin delivery options with reduced device-management requirements. Disposable designs can offer greater convenience by limiting maintenance and simplifying device replacement, which may improve usability for patients seeking less complex treatment routines. Increasing interest in patient-centric diabetes management and portable delivery technologies is creating additional opportunities for disposable insulin pump adoption.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Hospitals, Homecare Settings, Others	Hospitals	Homecare Settings
Product	Tethered Pumps, Disposable Pumps	Tethered Pumps	Disposable Pumps
Type	Traditional Insulin Pumps, Patch Pumps	Traditional Insulin Pumps	Patch Pumps
Accessories	Reservoirs, Infusion Sets, Batteries, Others	Infusion Sets	Reservoirs

Competitive Landscape and Market Positioning

Key companies in the insulin pumps market:

1. Medtronic plc (Ireland)

2. Insulet Corporation (United States)

3. Tandem Diabetes Care Inc. (United States)

4. Roche Holding AG (Switzerland)

5. Ypsomed AG (Switzerland)

6. Sanofi S.A. (France)

7. SOOIL Development Co. Ltd. (South Korea)

8. Cellnovo Group S.A. (France)

9. Valeritas Holdings Inc. (United States)

10. Jiangsu Delfu Medical Device Co. Ltd. (China)

The insulin pumps market is witnessing significant transformation through the integration of continuous glucose monitoring systems and automated insulin delivery technologies. Manufacturers are emphasizing compact designs, real-time monitoring, and smartphone connectivity to improve diabetes management efficiency. Increasing awareness regarding personalized healthcare solutions is further encouraging adoption of advanced insulin pump systems.

Industry Development/News

Company Name	Date	Key Development
ViCentra	May-26	ViCentra initiated commercial-scale manufacturing of its Kaleido insulin pump technology via its partnership with Phillips Medisize. The initiative triples production capacity to support large-scale supply readiness for over 17,000 European users, significantly strengthening the company's ability to scale automated insulin delivery infrastructure.
Insulet	May-26	Insulet initiated a massive recall of approximately 7 million patch pumps following a serious leak risk linked to tubing tears. Associated with multiple serious adverse events, this second device recall within a year impacts competitive positioning and raises significant market concerns regarding the manufacturing quality and reliability of patch-based insulin delivery systems.
Diabeloop	May-26	Diabeloop obtained CE Mark approval for its DBLG2 automated insulin delivery system, initiating a phased European rollout. The algorithm integrates Dexcom G7 continuous glucose monitoring with ViCentra's Kaleido and Dana-i insulin delivery platforms, expanding the market availability of AI-driven diabetes management solutions and strengthening interoperable device ecosystems.
Medtronic	Apr-25	Medtronic advanced its collaboration with Abbott by submitting an interoperable insulin pump for FDA review. Designed to integrate directly with Abbott's continuous glucose monitoring ecosystem, the strategic submission accelerates the industry transition toward interoperable diabetes management frameworks and provides patients with expanded device combinations.
Sequel	Mar-24	Sequel secured FDA clearance for its Twist Automated insulin delivery system, introducing the first platform capable of directly measuring volume with each delivered dose. By integrating with Tidepool Loop technology for automated adjustments via continuous glucose monitor readings, the launch brings enhanced dosing precision and automated loop capabilities to the market.